The race to engineer new knobs for the human brain
Short summary
China is running seven clinical trials using chemogenetics, a technique that lets doctors control specific neurons with designer drugs, but the current approach uses clozapine at ultra-low doses instead of truly inert compounds, raising questions about precision and safety. The technology is sound for treating epilepsy and Parkinson's disease, though next-generation versions could be significantly better.
- Seven ongoing trials in China are testing chemogenetics for epilepsy, Parkinson's disease, and pain by injecting modified genes into the brain that make neurons respond to clozapine taken orally—affecting roughly 10 patients so far.
- Clozapine is used at 1% of the antipsychotic dose in Parkinson's trials and similarly low in epilepsy trials, minimizing off-target effects, but it's still not truly inert and requires long-term monitoring for rare idiosyncratic reactions like agranulocytosis.
- Current trials use hM4Di, which is only 2 amino acids different from the native human M4 receptor, reducing immune rejection risk, but genuinely inert alternatives like DCZ exist and could improve precision in future versions—they just haven't been approved for human use yet.
Full summary
Chemogenetics just entered human clinical trials, and Bryan Roth announced seven ongoing studies in China targeting epilepsy, Parkinson's disease, and pain—roughly 10 patients total so far. The technique works by using a modified virus to deliver a synthetic receptor gene into specific neurons. Once expressed, these designer receptors sit dormant until a patient takes an oral drug (typically clozapine at very low doses) that binds only to that synthetic receptor, causing the neuron to fire or inhibit depending on the setup. For epilepsy specifically, this offers a major advantage: instead of sedating the entire brain like benzodiazepines do, chemogenetics can silence runaway activity only at the seizure's focal point. The logic is sound—primate studies show it works—and the effect is reversible by simply stopping the medication, making it safer than permanent gene-editing approaches.
The current trials use clozapine as their "designer drug," but there's a catch. Clozapine isn't actually inert or novel—it's an antipsychotic that binds to multiple receptors throughout the brain. The researchers compensate by using doses around 1% of what's needed for schizophrenia treatment, betting that the synthetic receptor has much higher affinity for clozapine than the off-target ones do. This works, but it's a workaround. The original plan was to use CNO, which was supposed to be naturally inactive, but it barely crosses the blood-brain barrier and metabolizes into clozapine anyway, so that fell apart.
The author makes clear that these first-generation trials aren't as precise as the technology could be in theory. The real win here is proof-of-concept: chemogenetics can actually treat human disease. But there's room to improve. A truly inert designer drug and better targeting strategies could make next-generation chemogenetics work for less severe conditions and with fewer side effects. Right now, chemogenetics is niche and rough around the edges. As the author notes, this is as bad as it's going to get—the foundation is there for something much more refined.